Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

SAGE

Sage Therapeutics Inc

Jun 10 • 04:00PM ET

10.90

Dollar change +0.32
Percentage change 3.02	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: XBI VTI VB IWM VXF VBK PBE IWO IBB LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-8.40	Insider Own	17.76%	Shs Outstand	60.04M	Perf Week	-1.89%
Market Cap	655.96M	Forward P/E	-	EPS next Y	-5.14	Insider Trans	0.00%	Shs Float	49.49M	Perf Month	-11.67%
Income	-503.14M	PEG	-	EPS next Q	-1.65	Inst Own	90.58%	Short Float	17.09%	Perf Quarter	-48.54%
Sales	91.06M	P/S	7.20	EPS this Y	27.95%	Inst Trans	0.73%	Short Ratio	7.57	Perf Half Y	-47.82%
Book/sh	11.73	P/B	0.93	EPS next Y	21.17%	ROA	-50.61%	Short Interest	8.46M	Perf Year	-80.78%
Cash/sh	11.94	P/C	0.91	EPS next 5Y	16.80%	ROE	-54.72%	52W Range	10.44 - 59.99	Perf YTD	-49.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.28%	ROI	-71.29%	52W High	-81.83%	Beta	0.90
Dividend TTM	-	Quick Ratio	12.22	Sales past 5Y	3395.58%	Gross Margin	96.12%	52W Low	4.46%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	12.22	EPS Y/Y TTM	10.43%	Oper. Margin	-557.93%	RSI (14)	39.63	Volatility	5.72% 6.43%
Employees	487	Debt/Eq	0.00	Sales Y/Y TTM	868.87%	Profit Margin	-552.52%	Recom	2.76	Target Price	20.56
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	26.68%	Payout	-	Rel Volume	1.08	Prev Close	10.58
Sales Surprise	50.21%	EPS Surprise	-9.16%	Sales Q/Q	139.89%	Earnings	Apr 25 BMO	Avg Volume	1.12M	Price	10.90
SMA20	-4.98%	SMA50	-18.83%	SMA200	-43.58%	Trades		Volume	1,458,347	Change	3.02%

Date	Action	Analyst	Rating Change	Price Target Change
May-29-24	Initiated	Robert W. Baird	Neutral	$15
May-29-24	Initiated	Citigroup	Sell	$8
Apr-17-24	Downgrade	BofA Securities	Neutral → Underperform	$24 → $14
Dec-12-23	Initiated	Deutsche Bank	Hold	$21
Aug-08-23	Downgrade	Needham	Buy → Hold
Aug-08-23	Downgrade	Goldman	Buy → Neutral	$22
Aug-08-23	Downgrade	Canaccord Genuity	Buy → Hold	$64 → $21
Aug-07-23	Downgrade	Wedbush	Outperform → Neutral	$51 → $22
Aug-07-23	Downgrade	Stifel	Buy → Hold	$60 → $22
Aug-07-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$71 → $25
Aug-07-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-07-23	Downgrade	BofA Securities	Buy → Neutral	$66 → $25
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Mar-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$40 → $60
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Nov-01-22	Initiated	Loop Capital	Hold	$41
Mar-31-22	Initiated	Berenberg	Hold	$37
Nov-02-21	Upgrade	Guggenheim	Neutral → Buy	$55
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight	$78 → $66
Oct-07-21	Downgrade	Jefferies	Buy → Hold	$100 → $50

Show Previous Ratings

Today 06:30AM	Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntingtons Disease (Business Wire)
Jun-05-24 06:30AM	Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 12:12PM	Baird predicts steady growth for SAGE Therapeutics at $15 target (Investing.com) -8.97%
09:52AM	American downgraded, United upgraded: Wall Street's top analyst calls (The Fly)
May-13-24 07:57PM	15 Most Depressed States in the US (Insider Monkey)
06:30AM	Loading…
May-07-24 06:30AM	Sage Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
Apr-30-24 12:57PM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-26-24 11:27AM	Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates (Zacks)
Apr-25-24 02:33PM	Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained (MT Newswires)
10:54AM	SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:04AM	Sage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progress (GuruFocus.com)
07:35AM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Apr-18-24 11:37AM	Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal (Zacks)
10:01AM	Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
04:10PM	Loading…
Apr-17-24 04:10PM	Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark (Investor's Business Daily) -19.58%
02:41PM	Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data (Benzinga)
08:46AM	Sage Therapeutics Hammered After Parkinson's Drug Misses The Mark (Investor's Business Daily)
07:44AM	Sages cognition drug fails in Parkinsons study (BioPharma Dive)
06:39AM	Sage Therapeutics' Parkinson's drug fails in mid-stage study (Reuters)
06:30AM	Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease (Business Wire)
Apr-11-24 07:29PM	12 Best All-Time Low Stocks To Invest In (Insider Monkey)
06:30AM	Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 (Business Wire)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
07:47AM	New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way. (BioPharma Dive)
Mar-18-24 10:16AM	25 Most Stressed Cities in the United States (Insider Monkey)
Mar-15-24 11:30AM	Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? (Zacks)
Feb-28-24 06:30AM	Sage Therapeutics to Present at Upcoming March Investor Conferences (Business Wire)
Feb-15-24 01:36PM	Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates (Zacks)
10:50AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:15AM	Loading…
Feb-14-24 07:15AM	Sage Therapeutics Inc (SAGE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +11.86%
06:42AM	Sage offers details on launch of new postpartum depression pill (BioPharma Dive)
06:30AM	Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Feb-07-24 10:00AM	Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jan-31-24 06:30AM	Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 (Business Wire)
Jan-08-24 06:32AM	Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +16.91%
06:30AM	Sage Therapeutics Announces Changes to Board of Directors (Business Wire)
Jan-02-24 06:30AM	Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.03%
Dec-14-23 06:30AM	ZURZUVAE (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. (Business Wire)
Dec-07-23 11:31AM	Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report? (Zacks)
Nov-13-23 11:13AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 01:11PM	Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5% (Zacks) -5.76%
07:59AM	Biogens Earnings Top Estimates. Wall Street Still Has Questions About Growth. (Barrons.com)
06:30AM	Sage Therapeutics to Present at Upcoming November Investor Conferences (Business Wire)
Nov-07-23 06:02PM	Why Sage Therapeutics Stock Sank Today (Motley Fool)
05:41PM	Biogen Reports Earnings Wednesday. Heres What to Expect. (Barrons.com)
12:40PM	UPDATE 1-Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
08:44AM	Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
07:40AM	Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:21AM	Sage Therapeutics Inc (SAGE) Announces Q3 2023 Financial Results and Highlights Pipeline Progress (GuruFocus.com)
06:30AM	Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
06:30AM	Biogen, Sage set price of postpartum depression pill at $15,900 (BioPharma Dive)
Nov-02-23 10:00AM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-31-23 10:01AM	Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-24-23 06:42AM	Aristotle Atlantic's Large Cap Growth Strategy Sold Sage Therapeutics (SAGE) on Uncertainty Surrounding the Company (Insider Monkey)
06:30AM	Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 (Business Wire)
Oct-19-23 12:16PM	Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag (Zacks) -5.07%
Oct-18-23 06:30AM	Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntingtons Disease (Business Wire)
Oct-14-23 01:14PM	5 Stocks to Buy with Exponential Growth (Insider Monkey)
Sep-15-23 03:01PM	Sage Therapeutics to lose 95 employees in Cambridge in mass layoff (American City Business Journals)
Sep-13-23 04:43PM	Sage Therapeutics reveals number of layoffs in Raleigh (American City Business Journals)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
06:30AM	Sage Therapeutics to Present at Upcoming September Investor Conferences (Business Wire)
Sep-01-23 03:51PM	FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected (Investor's Business Daily)
01:27PM	Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why (Zacks)
Aug-31-23 11:10AM	Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment (Investor's Business Daily)
10:10AM	Sage cuts nearly half its staff in wake of partial FDA rejection (American City Business Journals)
09:36AM	Midday movers: Salesforce, Dollar General, Crowdstrike and more (Investing.com)
07:00AM	UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback (Reuters)
06:44AM	Sage Therapeutics to cut about 188 jobs after depression drug setback (Reuters)
06:40AM	Sage Therapeutics to cut 40% of jobs after depression drug setback (Reuters)
06:30AM	Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch and Pipeline Advancement (Business Wire)
Aug-24-23 10:23AM	3 Very Oversold Pharma Stocks to Buy Right Now (InvestorPlace)
05:10AM	Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? (Motley Fool)
Aug-11-23 12:05PM	15 Most Important Medical Discoveries in History (Insider Monkey) +12.45%
11:23AM	Why Shares of Sage Therapeutics Slumped This Week (Motley Fool)
10:34AM	Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News (Zacks)
08:50AM	2 Beaten-Down Stocks That Still Aren't Worth Buying (Motley Fool)
Aug-08-23 09:42AM	Company News for Aug 8, 2023 (Zacks) +13.01%
09:00AM	Is Sage Therapeutics a Contrarian Buy? (Motley Fool)
06:02AM	Analysts Just Made A Major Revision To Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts (Simply Wall St.)
Aug-07-23 04:06PM	Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug (Investor's Business Daily) -53.60%
03:50PM	Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug (Investopedia)
11:58AM	Sage Therapeutics Shares Plunge After FDA Rejection (TheStreet.com)
11:44AM	Why Sage Therapeutics Stock Is Crashing Today (Motley Fool)
10:32AM	Sage shares cut in half after postpartum drug approval. Here's what happened. (American City Business Journals)
10:32AM	Sage market cap cut in half as markets open after partial drug approval (American City Business Journals)
10:14AM	FDA approves first postpartum depression pill from Biogen, Sage (Yahoo Finance Video)
10:04AM	Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage (Barrons.com)
09:57AM	American downgraded, United upgraded: Wall Street's top analyst calls (The Fly)
09:57AM	American Airlines downgraded, United upgraded: Wall Street's top analys (The Fly)
08:09AM	Sage Stock Tumbles After FDA Decision on Depression Drug (Barrons.com)
08:06AM	Sage Stock Tumbles as Depression Pill Approval Omits Major Disorder (Bloomberg)
07:40AM	Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Aug-04-23 10:45PM	Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 (Business Wire)
10:42PM	FDA Approves ZURZUVAE (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder (Business Wire)
08:44PM	Postpartum depression drug developed by Sage, Biogen approved by FDA (American City Business Journals)
08:13PM	UPDATE 2-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression (Reuters)

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IGUCHI KIMI	CFO & Treasurer	Jan 02 '24	Option Exercise	1.36	1,642	2,233	70,429	Jan 04 04:07 PM
Barrett Elizabeth	Director	Aug 09 '23	Buy	18.64	2,000	37,279	3,000	Aug 11 08:51 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SAGE

Sage Therapeutics Inc

Upgrade your FINVIZ experience